Key clinical point: Atogepant shows a favorable safety and efficacy profile in the prophylactic treatment of episodic migraine.
Major finding: Atogepant (10 mg, 30 mg, and 60 mg) vs. placebo caused a significant reduction in mean monthly migraine ( P < .00001, P < .00001, and P = .007; respectively), headache ( P < .00001, P < .00001, and P = .001; respectively), and medication use (all P < .00001) days; an increase in the ≥50% responder rate ( P = .0008, P = .02, and P = .04; respectively); and a nonsignificant difference in the outcomes of adverse events ( P = .57, P = .64, and P = .68; respectively).
Study details: Findings are from a meta-analysis of 3 randomized controlled trials including 2,466 adult patients with episodic migraine who received atogepant (10 mg, 30 mg, or 60 mg once daily) or placebo.
Disclosures: The study was supported by the Suzhou Health Talents Training Project. None of the authors declared any conflicts of interest.
Source: Tao X et al. J Headache Pain. 2022;23:19 (Jan 29). Doi: 10.1186/s10194-022-01391-2